- cafead   Jul 22, 2020 at 10:52: AM
via Vesigen Therapeutics has raised $28.5 million from groups including Bayer. The series A round sets the Harvard University spinout up to build on technology that could redefine how RNAi, mRNA and CRISPR/Cas9 are delivered.
article source
article source